Intravitreal Bevacizumab (Avastin) for Myopic Choroidal Neovascularization
- 27 June 2007
- journal article
- clinical trial
- Published by Elsevier in Ophthalmology
- Vol. 114 (12), 2190-2196.e2
- https://doi.org/10.1016/j.ophtha.2007.03.043
Abstract
No abstract availableKeywords
Funding Information
- Research Grants Council, University Grants Committee (4140/02M)
This publication has 33 references indexed in Scilit:
- Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot studyBritish Journal of Ophthalmology, 2007
- Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopiaBritish Journal of Ophthalmology, 2007
- Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopiaBritish Journal of Ophthalmology, 2007
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- Antiproliferative and cytotoxic properties of bevacizumab on different ocular cellsBritish Journal of Ophthalmology, 2006
- Choroidal neovascularisation in pathological myopia: an update in managementBritish Journal of Ophthalmology, 2005
- Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularizationActa Ophthalmologica Scandinavica, 2005
- Bevacizumab suppresses choroidal neovascularisation caused by pathological myopiaBritish Journal of Ophthalmology, 2005
- Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia—1-year results of a prospective seriesEye, 2004
- Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularizationOphthalmology, 1999